@Article{096504018X15368325811545,
AUTHOR = {Ping Wen, Sheng-Duo Chen, Jia-Rui Wang, Ying-He Zeng},
TITLE = {Comparison of Treatment Response and Survival Profiles  Between Drug-Eluting Bead Transarterial Chemoembolization  and Conventional Transarterial Chemoembolization in Chinese  Hepatocellular Carcinoma Patients: A Prospective Cohort Study},
JOURNAL = {Oncology Research},
VOLUME = {27},
YEAR = {2019},
NUMBER = {5},
PAGES = {583--592},
URL = {http://www.techscience.com/or/v27n5/48574},
ISSN = {1555-3906},
ABSTRACT = {This study evaluated the difference in treatment response and survival profiles between drug-eluting bead 
transarterial chemoembolization (DEB-TACE) and conventional transarterial chemoembolization (cTACE) 
treatments in Chinese hepatocellular carcinoma (HCC) patients. A total of 120 HCC patients were consecutively enrolled in this prospective cohort study, which showed that DEB-TACE achieved higher complete 
response (CR) (30.8%) compared with cTACE (7.4%) with no difference in overall response rate (ORR) for 
patients treated with DEB-TACE and cTACE (80.8% vs. 73.5%). In addition, DEB-TACE was associated with 
a lower rate of progressive disease (PD) compared with cTACE (1.9% vs. 11.8%). With respect to survival, 
patients in the DEB-TACE group achieved median progression-free survival (PFS) of 15 months (95% CI 
12–18 months), which was longer than the cTACE group [median PFS 11 months (95% CI 10–12 months)]. 
Median overall survival (OS) was also longer with DEB-TACE [25 months (95% CI 22-28 months)] when 
compared with cTACE [21 months (95% CI 18–24 months)]. Univariate and multivariate logistic regression 
analysis showed that DEB-TACE was an independent predictive factor for achieving CR. Univariate Cox’s 
regression analysis revealed that DEB-TACE was a predictive factor for prolonged PFS and OS, while multivariate analysis demonstrated that DEB-TACE was not an independent factor for predicting PFS or OS. In 
conclusion, we found that DEB-TACE achieved higher treatment response and prolonged survival compared 
with cTACE in Chinese HCC patients.},
DOI = {10.3727/096504018X15368325811545}
}